Search

Author/Creator Han, Chenglong

1. AB0745 ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL. (June 2019)

Authors:
Deodhar, Atul; Bruce Kirkham, L; Rahman, Proton; Helliwell, Philip; Gottlieb, Alice B.; Boehncke, Wolf-Henning; Xu, Xie L.; Han, Chenglong
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78(2019)Supplement 2
Page Start:
1838
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1. (17th February 2022)

Authors:
Griffiths, Christopher E. M.; Papp, Kim A.; Song, Michael; Miller, Megan; You, Yin; Shen, Yaung-Kaung; Han, Chenglong; Blauvelt, Andrew
Journal:
Journal of dermatological treatment
Issue:
Volume 33:Number 2(2022)
Page Start:
848
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies. Issue 3 (July 2019)

Authors:
Gordon, Kenneth B.; Han, Chenglong; Li, Shu; You, Yin; Song, Michael; Fakharzadeh, Steven; Crowley, Jeffrey J.; Reich, Kristian
Journal:
Journal of psoriasis and psoriatic arthritis
Issue:
Volume 4:Issue 3(2019)
Page Start:
147
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. (17th February 2020)

Authors:
Ferris, Laura K.; Ott, Elyssa; Jiang, Jingzhi; Hong, H. Chih-Ho; Li, Shu; Han, Chenglong; Baran, Wojciech
Journal:
Journal of dermatological treatment
Issue:
Volume 31:Number 2(2020)
Page Start:
152
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial. Issue 6 (26th May 2016)

Authors:
Emery, Paul; Fleischmann, Roy M.; Strusberg, Ingrid; Durez, Patrick; Nash, Peter; Amante, Eric Jason B.; Churchill, Melvin; Park, Won; Pons‐Estel, Bernardo; Han, Chenglong; Gathany, Timothy A.; Xu, Stephen; Zhou, Yiying; Leu, Jocelyn H.; Hsia, Elizabeth C.
Journal:
Arthritis care & research
Issue:
Volume 68:Issue 6(2016:Jun.)
Page Start:
744
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Efficacy and safety results from a Phase 3, randomized, placebo‐controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. (11th August 2015)

Authors:
Li, Zhanguo; Zhang, Fengchun; Kay, Jonathan; Fei, Kaiyin; Han, Chenglong; Zhuang, Yanli; Wu, Zhong; Hsia, Elizabeth C.
Journal:
International journal of rheumatic diseases
Issue:
Volume 19:Number 11(2016)
Page Start:
1143
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. (17th August 2020)

Authors:
Reich, Kristian; Foley, Peter; Han, Chenglong; McElligott, Sean; Muser, Erik; Li, Nan; Armstrong, April W.
Journal:
Journal of dermatological treatment
Issue:
Volume 31:Number 6(2020)
Page Start:
617
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗